Want to see EVMN full AI Analyst Report?
EVMN Stock Chart & Stats
$27.45
--
Market closed
$27.45
--
Day’s Range― - ―
52-Week Range$11.15 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)935.27K
Market Cap
$437.26M
Enterprise Value$253.29M
Total Cash (Recent Filing)$211.46M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)―
Beta-0.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue25.33
Enterprise Value/Gross Profit27.31
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$37.60Price Target Upside36.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line GrowthRevenue roughly tripled over 2023–2025, signaling durable commercial or partner revenue expansion. A sustained top‑line trend supports scaling R&D programs, helps absorb fixed costs over time, and improves the odds of achieving operating leverage as mid‑stage trials progress.
Recapitalized Balance SheetA material recapitalization sharply reduced leverage and turned equity strongly positive, lowering insolvency risk. This structural improvement gives management flexibility to fund mid‑stage programs, negotiate partnerships, and reduces short‑term refinancing pressure.
Multi-year Cash RunwayManagement states cash will support operations through 2028, providing multi‑year funding for Phase 2b programs. A secured runway is a durable enabler for executing clinical plans without immediate financing, critical for value realization in mid‑stage biotech.
Bears Say
Escalating Cash BurnOperating cash outflows have widened sharply year to year, reflecting rising R&D and operating investment. Persistently increasing cash burn is structural for a clinical biotech and raises the likelihood of future equity raises, program tradeoffs, or expense cuts absent faster revenue scaling.
Persistent Net LossesLarge, sustained net losses show the cost base materially outstrips current revenues. This delays self‑funding, increases dilution risk over the medium term, and constrains strategic optionality until programs reach later‑stage value inflection points.
Clinical Setback Increases Pipeline RiskThe Phase 2b failure in chronic spontaneous urticaria and halting that indication reduces program optionality and highlights translational uncertainty. Such attrition diverts R&D focus and resources, raising the effective risk profile of the pipeline despite ongoing work in other indications.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $11.15 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $437.26M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Currently, no data Available
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,018,370 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.60 (36.98% Upside)
$37.60 (36.98% Upside)
Blogger Sentiment
Bullish
EVMN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $146.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
475.65%
Trailing 12-Months
Company Description
Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$37.60
▲(36.98% Upside)
Ownership Overview
52.56% Insiders
10.70% Mutual Funds
10.56% Other Institutional Investors
23.57% Public Companies and
Individual Investors